AllerNaze approved for allergic rhinitis

AllerNaze (triamcinolone acetonide, from Collegium) 50mcg nasalspray has been approved for the treatment of nasal symptoms associatedwith seasonal and perennial allergic rhinitis in patients ≥12 years ofage. This approval was based on 14 controlled clinical trials involvingalmost 1200 patients assessing the safety and effectiveness ofAllerNaze in treating the symptoms (runny nose, nasal itching,sneezing, and nasal congestion) of patients with allergic rhinitis

For more information call (401) 762-2000 or visit www.collegiumpharma.com.